New drug therapies interfering with the renin-angiotensin-aldosterone system for resistant hypertension

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 14, Issue 4, 2013, Pages 285-289

  Monge, Matthieu ^a   Lorthioir, Aurélien ^a   Bobrie, Guillaume ^a   Azizi, Michel ^a,b  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

New drug; Renin angiotensin system; resistant hypertension

Indexed keywords

3 (1 BIPHENYL 4 YLMETHYL 3 ETHOXYCARBONYL 1 BUTYLCARBAMOYL)PROPIONIC ACID; 3 (1 BIPHENYL 4 YLMETHYL 3 ETHOXYCARBONYL 1 BUTYLCARBAMOYL)PROPIONIC ACID PLUS VALSARTAN; ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALDOSTERONE SYNTHASE; ALDOSTERONE SYNTHASE INHIBITOR; ALISKIREN; ANGIOTENSIN II ANTAGONIST; ANTIHYPERTENSIVE AGENT; BAY 94 8862; DAGLUTRIL; DARUSENTAN; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN CONVERTING ENZYME INHIBITOR; ENKEPHALINASE INHIBITOR; EPLERENONE; LCI 699; MINERALOCORTICOID RECEPTOR; NEW DRUG; PLACEBO; QGC 001; RENIN INHIBITOR; SPIRONOLACTONE; UNCLASSIFIED DRUG; VALSARTAN;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; BREAST TENDERNESS; CARDIOTOXICITY; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; FLUID RETENTION; GYNECOMASTIA; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPERTENSION; IMPOTENCE; MENSTRUAL IRREGULARITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PRIMARY HYPERALDOSTERONISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESISTANT HYPERTENSION; SIDE EFFECT; TREATMENT OUTCOME;

NEW DRUG; RENIN ANGIOTENSIN SYSTEM; RESISTANT HYPERTENSION;

ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM;

EID: 84889823658     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320313513408     Document Type: Article

References (39)

1. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013 ; 31: 1281-1357
2. Burnier M, Wuerzner G, Struijker-Boudier H, et al. Measuring, analyzing, and managing drug adherence in resistant hypertension. Hypertension. 2013 ; 62: 218-225
3. Jung O, Gechter JL, Wunder C, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013 ; 31: 766-774
4. Paulis L, Steckelings UM, Unger T. Key advances in antihypertensive treatment. Nat Rev Cardiol. 2012 ; 9: 276-285
5. Laurent S, Schlaich M, Esler M. New drugs, procedures, and devices for hypertension. Lancet. 2012 ; 380: 591-600
6. Azizi M, Menard J. Renin inhibitors and cardiovascular and renal protection: An endless quest?. Cardiovasc Drugs Ther. 2013 ; 27: 145-153
7. Azizi M, Lamarre-Cliche M, Labatide-Alanore A, et al. Physiologic consequences of vasopeptidase inhibition in humans: Effect of sodium intake. J Am Soc Nephrol. 2002 ; 13: 2454-2463
8. Campbell DJ. Vasopeptidase inhibition: A double-edged sword?. Hypertension. 2003 ; 41: 383-389 (Pubitemid 36314604)
9. Kostis JB, Packer M, Black HR, et al. Omapatrilat and enalapril in patients with hypertension: The Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004 ; 17: 103-111 (Pubitemid 38125125)
10. Sulpizio AC, Pullen MA, Edwards RM, et al. Mechanism of vasopeptidase inhibitor-induced plasma extravasation: Comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406. J Pharmacol Exp Ther. 2005 ; 315: 1306-1313 (Pubitemid 41635419)
11. Dhaun N, Goddard J, Kohan DE, et al. Role of endothelin-1 in clinical hypertension: 20 years on. Hypertension. 2008 ; 52: 452-459
12. Weber MA, Black H, Bakris G, et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: A randomised, double-blind, placebo-controlled trial. Lancet. 2009 ; 374: 1423-1431
13. Bakris GL, Lindholm LH, Black HR, et al. Divergent results using clinic and ambulatory blood pressures: Report of a darusentan-resistant hypertension trial. Hypertension. 2010 ; 56: 824-830
14. Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010 ; 50: 401-414
15. Ruilope LM, Dukat A, Bohm M, et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: A randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010 ; 375: 1255-1266
16. Seed A, Kuc RE, Maguire JJ, et al. The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sci. 2012 ; 91: 743-748
17. Ferro CJ, Spratt JC, Haynes WG, et al. Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation. 1998 ; 97: 2323-2330 (Pubitemid 28280386)
18. Dickstein K, De Voogd HJ, Miric MP, et al. Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure. Am J Cardiol. 2004 ; 94: 237-239 (Pubitemid 38902881)
19. Parvanova A, van der Meer IM, Iliev I, et al. Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: A randomised, crossover, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2013 ;:
20. Jansen PM, Danser AH, Imholz BP, et al. Aldosterone-receptor antagonism in hypertension. J Hypertens. 2009 ; 27: 680-691
21. Calhoun DA, White WB. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens. 2008 ; 2: 462-468
22. Brown NJ. Aldosterone and end-organ damage. Curr Opin Nephrol Hypertens. 2005 ; 14: 235-241 (Pubitemid 40685635)
23. Connell JM, MacKenzie SM, Freel EM, et al. A lifetime of aldosterone excess: Long-term consequences of altered regulation of aldosterone production for cardiovascular function. Endocr Rev. 2008 ; 29: 133-154 (Pubitemid 351519688)
24. Funder JW, Mihailidou AS. Aldosterone and mineralocorticoid receptors: Clinical studies and basic biology. Mol Cell Endocrinol. 2009 ; 301: 2-6
25. Menard J. The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol Cell Endocrinol. 2004 ; 217: 45-52 (Pubitemid 38596628)
26. Weinberger MH, Roniker B, Krause SL, et al. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002 ; 15: 709-716 (Pubitemid 34804277)
27. Parthasarathy HK, Menard J, White WB, et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens. 2011 ; 29: 980-990
28. Azizi M, Amar L, Menard J. Aldosterone synthase inhibition in humans. Nephrol Dial Transplant. 2013 ; 28: 36-43
29. Barfacker L, Kuhl A, Hillisch A, et al. Discovery of BAY 94-8862: A nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012 ; 7: 1385-1403
30. Fagart J, Hillisch A, Huyet J, et al. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem. 2010 ; 285: 29932-29940
31. Amar L, Azizi M, Menard J, et al. Aldosterone synthase inhibition with LCI699: A proof-of-concept study in patients with primary aldosteronism. Hypertension. 2010 ; 56: 831-838
32. Amar L, Azizi M, Menard J, et al. Sequential comparison of aldosterone synthase inhibition and mineralocorticoid blockade in patients with primary aldosteronism. J Hypertens. 2013 ; 31: 624-629
33. Calhoun DA, White WB, Krum H, et al. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation. 2011 ; 124: 1945-1955
34. Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: A randomized, double-blind trial. Eur Heart J. 2013 ; 34: 2453-2463
35. Zini S, Masdehors P, Lenkei Z, et al. Aminopeptidase A: Distribution in rat brain nuclei and increased activity in spontaneously hypertensive rats. Neuroscience. 1997 ; 78: 1187-1193 (Pubitemid 27223720)
36. Reaux A, Fournie-Zaluski MC, David C, et al. Aminopeptidase A inhibitors as potential central antihypertensive agents. Proc Natl Acad Sci U S A. 1999 ; 96: 13415-13420
37. de Mota N, Iturrioz X, Claperon C, et al. Human brain aminopeptidase A: Biochemical properties and distribution in brain nuclei. J Neurochem. 2008 ; 106: 416-428 (Pubitemid 351840224)
38. Bodineau L, Frugiere A, Marc Y, et al. Orally active aminopeptidase A inhibitors reduce blood pressure: A new strategy for treating hypertension. Hypertension. 2008 ; 51: 1318-1325 (Pubitemid 351555944)
39. Bodineau L, Frugiere A, Marc Y, et al. Aminopeptidase A inhibitors as centrally acting antihypertensive agents. Heart Fail Rev. 2008 ; 13: 311-319